Spotlight On... Kite and Roche team up in lymphoma; AstraZeneca buys Orexo's respiratory drug; and more...

Kite Pharma ($KITE) is teaming up with Roche's ($RHHBY) Genentech to study its CAR-T cancer therapy in tandem with the checkpoint inhibitor atezolizumab in blood cancer. Under the agreement, Kite and Roche are planning a Phase Ib/II combo study in non-Hodgkin lymphoma, planning to start enrollment this year. Kite's KTE-C19 works by re-engineering patients' own T cells to home in on the cancer antigen CD19, while Roche's in-development atezolizumab is designed to help unblind the immune system to malignancies. The partners believe a combination of the two treatments could have a promising future in a variety of cancer types. News

@FierceBiotech: ICYMI from FierceBiotechResearch: HIV drug increases therapeutic window for skin cancer by slowing drug resistance. Story | Follow @FierceBiotech

@JohnCFierce: As in everything, GSK moves SOOOOO slowly. CEO Witty will leave March, 2017. No rush. | Follow @JohnCFierce

AstraZeneca ($AZN) has traded $5 million for the full rights to partner Orexo's OX-CLI, a treatment for respiratory disease. More

Cellectis ($CLLS) partnered with MabQuest to work on antibodies targeting the protein PD-1 to boost the effect of T cells against cancer. Item

Medical Device News

@FierceMedDev: Med tech, healthcare services venture firm HealthQuest raises oversubscribed $225M fund. Story | Follow @FierceMedDev

@VarunSaxena2: The chart is just so darn startling/horrible. (Have mentioned it in stories about opioid abuse-deterrent tech.) More from the NYT | Follow @VarunSaxena2

@EmilyWFierce: 10X Genomics locks down $55M for long-read sequencing tech. News | Follow @EmilyWFierce

Toshiba sell its medical imaging business to Canon for $6B amid deepening accounting scandal. Report

Dx Digest: Myriad reveals positive study results for melanoma test; Guardant Health looks to cancer analytics for liquid biopsy. Article

Pharma News

**@FiercePharma:**India's Lupin hauled up by U.S. FDA for lapses at Goa plant. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch. More from FiercePharmaMarketing | Follow @CarlyHFierce

Chicago psychiatrist slapped with prison time in Teva kickbacks case. More

GlaxoSmithKline CEO packs his bags for March 2017 exit. Article

CRO News

INC snags a Quintiles vet as its new science leader. More

Covance launches mobile health suite for clinical trials. Report

PDS Life Sciences launches new FDA data compliance service. Story

Quotient Clinical expands into Japan after PE buyout. Article

Pharma M****anufacturing News

Contract manufacturer PCT will handle TxCell production in U.S. Item

European drug regulators find lots of plant issues in first quarter. Story

China's FDA urged to get track-and-trace system in place. Item

FDA castigates India's Emcure for routinely faking data. Report

P&G joins Pfizer and Abbott in fighting India's cough med ban. Article

Pharma Asia News

Chi-Med raises $101.25M in IPO, joining China's BeiGene on Nasdaq. News

Abbott India unit, others, get court stay on fixed-dose drug bans. Item

U.S. biotech Quark's siRNA trials include China, India legs. Report

Nasdaq exec says biotechs prime Asian unicorns for listings. Story

India's Lupin hauled up by U.S. FDA for lapses at Goa plant. Article